Skip to content
OpenCapital
Get started

Icahn Enterprises IEP Pharma — Other Operating Revenue

Other segment segments

Automotive
$142M-6.0%

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$4.9B+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept iep:OtherOperatingRevenue.

The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Icahn Enterprises's pharma — other operating revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Icahn Enterprises's pharma — other operating revenue?
Icahn Enterprises (IEP) reported pharma — other operating revenue of $1M in Q1 2026.
What is the long-term trend for Icahn Enterprises's pharma — other operating revenue?
Over 4 years (2021 to 2025), Icahn Enterprises's pharma — other operating revenue has grown at a 5.7% compound annual growth rate (CAGR), from $4M to $5M.
What does pharma — other operating revenue mean?
Revenue generated by the pharmaceutical segment from activities outside of direct product sales, such as licensing fees, royalties, or contract manufacturing services. It provides insight into the diversification of the segment's income streams beyond core product distribution.